2017
DOI: 10.1093/eurheartj/ehx502.p2637
|View full text |Cite
|
Sign up to set email alerts
|

P2637ACE inhibitors and ARBs decrease more powerful the PTX-3 plasma levels of hypertensive patients with endothelial dysfunction compared with other anti-hypertensive drugs, in a chronic treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…[19][20][21] In addition, there are studies on its potential superiority to CRP as a biomarker of cardiovascular disease due to its rapid response and ability to reflect vascular inflammation. 9,22,23 In a study conducted with childhood-onset systemic lupus erythematosus patients, it was found that serum PTX3 levels significantly increased in the presence of vasculitis, and it was reported that serum PTX3 levels could be useful in detecting subclinical vascular involvement. 24 In another study, serum PTX3 levels were found to be higher in patients with juvenile scleroderma than healthy controls, but there was no correlation with vascular complications.…”
Section: Discussionmentioning
confidence: 99%
“…[19][20][21] In addition, there are studies on its potential superiority to CRP as a biomarker of cardiovascular disease due to its rapid response and ability to reflect vascular inflammation. 9,22,23 In a study conducted with childhood-onset systemic lupus erythematosus patients, it was found that serum PTX3 levels significantly increased in the presence of vasculitis, and it was reported that serum PTX3 levels could be useful in detecting subclinical vascular involvement. 24 In another study, serum PTX3 levels were found to be higher in patients with juvenile scleroderma than healthy controls, but there was no correlation with vascular complications.…”
Section: Discussionmentioning
confidence: 99%
“…However, in contrast to CRP, it is produced locally in the inflamed tissue and in neutrophils [7]. There are indications that PTX3 may be superior to CRP as a biomarker of atherosclerotic cardiovascular diseases (CVD) (including acute coronary syndromes), possibly due to its ability to reflect vascular inflammation and due to the speed of its response [810]. Interestingly, the role of PTX3 in CVD may be protective, and PTX3 may represent a relevant therapeutic target [11,12].…”
Section: Introductionmentioning
confidence: 99%